E Therapeutics (LON:ETX) - Up and running
Jun 19th 2012 - Edison Investment Research today published a report on E Therapeutics (ETX.L, LSE:ETX, LON:ETX) entitled "Up And Running". In summary, the report says:
e-Therapeutics was busy behind the scenes during 2011, securing its funding base, strengthening its management team and board, revitalising its discovery activities and preparing for the start of new clinical trials. 2012 should be a year of execution. The first Phase I cancer trial of ETS2101 is now enrolling, a second is imminent and two other assets are due to enter the clinic this year. New hires and the opening of a network pharmacology hub mean the discovery division is fully active; and business development activity is ramping up. e-Therapeutics has been highly visible on the conference circuit, raising the profile of its network pharmacology platform and existing pipeline. It is well positioned as a discovery partner given growing industry...
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
